Good point about monitoring Heart function Sammy...in hindsight this should have been covered in P2 but here we are...
Your thinking could well be spot on, importantly that framework covers 100% of DMD boys.
Sarepta currently only have a drug for 20% of the boys, and revenues expected to top $500m per year in 2021.
Commercially speaking - the rewards for Big Pharma here are massive if we get success in P2B for ambulant and non-ambulant boys.
Another reason why the $1B Roche <-> Sarepta deal should be the benchmark for partnership.
My comments re "combination therapy" stem from Sarepta's predicament with Exondys and needing to provide FDA with efficacy data to protect revenues...let alone their gene therapy.
Exciting times.
- Forums
- ASX - By Stock
- PER
- Ann: ATL1102 DMD Paediatric Investigation Plan submitted to EMA
Ann: ATL1102 DMD Paediatric Investigation Plan submitted to EMA, page-27
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
13.5¢ |
Change
0.005(3.85%) |
Mkt cap ! $121.7M |
Open | High | Low | Value | Volume |
13.5¢ | 13.5¢ | 13.0¢ | $378.0K | 2.903M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 5000 | 13.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
13.5¢ | 516956 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 5000 | 0.130 |
4 | 1441013 | 0.125 |
7 | 89909 | 0.120 |
4 | 1061892 | 0.115 |
5 | 322225 | 0.110 |
Price($) | Vol. | No. |
---|---|---|
0.135 | 516956 | 4 |
0.140 | 564703 | 9 |
0.145 | 162235 | 7 |
0.150 | 993514 | 9 |
0.155 | 150261 | 3 |
Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |
The Watchlist
JBY
JAMES BAY MINERALS LIMITED
Andrew Dornan, Executive Director
Andrew Dornan
Executive Director
SPONSORED BY The Market Online